


PHARMACEUTICAL 2021



Anixa Biosciences Inc Rank 359 of 409





PHARMACEUTICAL 2021



Anixa Biosciences Inc Rank 359 of 409

The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Anixa Biosciences Inc is the variable Net Income, reducing the Economic Capital Ratio by 390% points.

The company's Economic Capital Ratio, given in the ranking table, is -599%, being 245% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	9,369
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,189
Liabilities, Non-Current	0
Other Assets	84
Other Compr. Net Income	0
Other Expenses	148
Other Liabilities	0
Other Net Income	34
Property and Equipment	0
Research and Development	4,381
Revenues	0
Selling, General and Administrative Expense	5,597

Output Variable	Value in 1000 USD
Assets	9,453
Liabilities	1,189
Expenses	10,126
Stockholders Equity	8,264
Net Income	-10,092
Comprehensive Net Income	-10,092
Economic Capital Ratio	-599%